Healio

‘Diffusion of responsibility’ leads to missed testing in colon cancer

Please provide your email address to receive an email when new articles are posted on . ORLANDO — Though up to 17% of early-onset colon cancers carry genetic markers for Lynch syndrome, only 30% of ...
Healio

Q&A: Protocols needed to overcome ‘diffusion of responsibility,’ maximize Lynch syndrome testing

Please provide your email address to receive an email when new articles are posted on . Researchers have identified inconsistent beliefs among medical specialists as to who is responsible for ordering ...
Nasdaq

Planned study features noted principal investigator, regulatory flexibility, and immediate availability of patients

CHARLOTTESVILLE, Va., May 20, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for ...